Supplementary Online Content

Grasselli G, Greco M, Zanella A, et al; for the COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with coronavirus disease 2019 in intensive care units in Lombardy, Italy. Published online July 15, 2020. *JAMA Intern Med.* doi:10.1001/jamainternmed.2020.3539

eMethods. Definitions

eFigure 1. Missing Data

eFigure 2. Outcomes According to ICU Admission Date

eFigure 3. Multivariable Model Including Baseline Characteristics, Comorbidities, Medications, and Physiological Variables at Admission

eFigure 4. Survival According to Use of Noninvasive Ventilation at Admission

eTable 1. Different Characteristics of Patients According to Noninvasive Ventilation or Invasive Mechanical Ventilation at Admission

eTable 2. Previous Medication Use in the Overall Population and in the Subpopulation of Patients With History of Hypertension

This supplementary material has been provided by the authors to give readers additional information about their work.

eMethods. Definitions

Definition of drug category according to regional database

The categories of medications, used in this paper, are defined according to the following list of medications extracted from regional database

Angiotensin-converting-enzyme inhibitors (ACE-I): a patient taking any of the following:

"BENAZEPRIL", "CAPTOPRIL E DIURETICI", "CAPTOPRIL", "CILAZAPRIL E DIURETICI", "DELAPRIL E DIURETICI", "DELAPRIL E DIURETICI", "ENALAPRIL E DIURETICI", "ENALAPRIL E DIURETICI", "ENALAPRIL E DIURETICI", "FOSINOPRIL", "FOSINOPRIL E DIURETICI", "LISINOPRIL E DIURETICI", "MOEXIPRIL E DIURETICI", "PERINDOPRIL", "PERINDOPRIL", "PERINDOPRIL E AMLODIPINA E INDAPAMIDE", "PERINDOPRIL E AMLODIPINA", "PERINDOPRIL E BISOPROLOLO", "PERINDOPRIL E DIURETICI", "QUINAPRIL E DIURETICI", "VALSARTAN E DIURETICI", "ZOFENOPRIL E DIURETICI", "BENAZEPRIL E DIURETICI", "RAMIPRIL E FELODIPINA"

Angiotensin II receptor blockers (ARB): a patient taking any of the following:

"CANDESARTAN", "EPROSARTAN", "EPROSARTAN E DIURETICI", "IRBESARTAN", "IRBESARTAN E DIURETICI", "OLMESARTAN MEDOXOMIL", "OLMESARTAN MEDOXOMIL E AMLODIPINA", "OLMESARTAN MEDOXOMIL E DIURETICI", "TELMISARTAN", "TELMISARTAN E DIURETICI", "VALSARTAN", "VALSARTAN E SACUBITRIL", "CANDESARTAN E AMLODIPINA", "CANDESARTAN E DIURETICI"

Beta-blocker: a patient taking any of the following:

"ATENOLOLO", "ATENOLOLO ED ALTRI DIURETICI", "BISOPROLOLO", "BISOPROLOLO E TIAZIDI", "CARVEDILOLO", "METOPROLOLO", "NEBIVOLOLO", "NEBIVOLOLO E TIAZIDI", "PROPRANOLOLO", "SOTALOLO"

Anti-hypertensive drugs: a patient taking any of the following. This category was not used as a drug category, but to define hypertension (see comorbidities)

"AMLODIPINA", "BARNIDIPINA", "CLONIDINA", "DILTIAZEM", "DOXAZOSIN", "EPLERENONE", "FELODIPINA", "LACIDIPINA", "LERCANIDIPINA", "MANIDIPINA", "MOXONIDINA", "NIFEDIPINA", "VERAPAMIL"

Plus drugs comprised under categories ACE-I / ARB / Beta blockers

Statin: a patient taking any of the following:

"ATORVASTATINA", "ATORVASTATINA, AMLODIPINA E PERINDOPRIL", "FLUVASTATINA", "LOVASTATINA", "PRAVASTATINA", "ROSUVASTATINA", "ROSUVASTATINA E EZETIMIBE", "SIMVASTATINA", "SIMVASTATINA ED EZETIMIBE"

Corticosteroids: a patient taking any of the following:

BETAMETASONE", "BETAMETASONE ED ANTIBIOTICI", "BUDESONIDE", "CORTISONE", "DESAMETASONE", "METILPREDNISOLONE", "METILPREDNISOLONE ACEPONATO", "PREDNISONE", "TRIAMCINOLONE"

©2020 American Medical Association. All rights reserved.

Immunosuppressive agent: a patient taking any of the following:

"AZATIOPRINA", "CICLOSPORINA", "EVEROLIMUS", "TACROLIMUS", "LEFLUNOMIDE", "SIROLIMUS"

Or a drug comprised under category steroids

Diuretics: a patient taking any of the following:

"ACETAZOLAMIDE", "CANRENOATO DI POTASSIO", "CANRENONE", "CLORTALIDONE", "FUROSEMIDE", "FUROSEMIDE E FARMACI RISPARMIATORI DI POTASSIO", "IDROCLOROTIAZIDE",

"IDROCLOROTIAZIDE E FARMACI RISPARMIATORI DI POTASSIO", "INDAPAMIDE",

"SPIRONOLATTONE", "TORASEMIDE")

Antiplatelet medications: a patient taking any of the following:

"ACIDO_ACETILSALICILICO", "CLOPIDOGREL", "PRASUGREL", "TICAGRELOR", "TICLOPIDINA"

Anticoagulants: a patient taking any of the following:

"ACENOCUMAROLO", "APIXABAN", "BEMIPARINA", "DABIGATRAN_ETEXILATO", "EDOXABAN", "ENOXAPARINA", "EPARINICI", "FONDAPARINUX", "NADROPARINA", "PARNAPARINA", "RIVAROXABAN", "WARFARIN"

$Definition \ of \ comorbidities \ from \ regional \ database$

Comorbidities used in this study are derived from regional database as follows

	Cardiova						LIVER		
	Hypert	hyperchole	Diabetes	scular	Malig			DISEA	
	ension	sterolemia	type 2	disease	nancy	COPD	CKD	SE	Other
ARTERIAL	01101011	Ctorolonia	1.5 20 2	Giodado	riaricy	00.5	U. C.		0 11101
HYPERTENSION	1								
HYPERCHOLESTERO									
LEMIA, FAMILIAR AND									
NOT		1							
DIABETES MELLITUS									
TYPE 2			1						
ISCHEMIC									
CARDIOMYOPATHY				1					
NON ARRHYTHMIC				_					
CARDIOMIOPATHY ARRHYTHMIC				1					
CARDIOMIOPATHY				1					
HYPOTHYROIDISM				!					4
NEOPLASIA,									1
FOLLOW-UP					1				
NEOPLASIA,					1				
REMISSION					1				
ACTIVE NEOPLASIA					1				
					1				
HEART FAILURE				1					
COPD						1			
CHRONIC KIDNEY									
DISEASE							1		
CHRONIC HEPATITIS								1	
ASTHMA									1
CEREBRAL									
VASCULOPATHY									1
ARTERIAL									
VASCULOPATHY									1
VALVULAR									
CARDIOMYOPATHY				1					
DIABETES MELLITUS									
TYPE 2, COMPLICATED			1						
HASHIMOTO			1						
THYROIDITIS									1
VENOUS									
VASCULOPATHY									1
EPILEPSY									1
RHEUMATOID	<u> </u>				1		<u> </u>		† '
ARTHRITIS									1
BASEDOW- GRAVES									<u> </u>
DISEASE AND									
HYPERTHYROIDISM									1
PSORIASIS AND									
PSORIATIC									
ARTHRITIS									1
INACTIVE									
TRANSPLANT									1
HEPATIC CIRRHOSIS			20 Amorio					1	

CDOUNDICEACE AND		I			
CROHN DISEASE AND					
ULCERATIVE COLITIS					
(IBD)					1
HIV POSITIVE AND					
OVERT AIDS					1
PARKINSON E					
PARKINSONISMS					1
RESPIRATORY					
FAILURE/ OXIGEN					
THERAPY					1
SYSTEMIC LUPUS					
ERYTHEMATOUS					11
NERVOUS SYSTEM					
AND SENSORY					
ORGANS DISEASES					1
MIASTENIA GRAVIS					1
HYPER AND					
HYPOPARATHYROIDI					
SM					1
OSTEOMUSCULAR					
AND CONNECTIVE					
TISSUE DISEASES					1
ENDOCRINE,					
NUTRITIONAL AND					
METABOLIC					
DISEASES					1
MULTIPLE					•
SCLEROSIS					1
DIABETES MELLITUS					<u> </u>
TYPE 1,					
COMPLICATED					1
DIABETES MELLITUS					<u> </u>
TYPE 1					1
CARDIOVASCULAR					<u> </u>
DISEASES					1
CONGENITAL					•
MALFORMATIONS					1
CHRONIC					•
PANCREATITIS					1
AUTOIMMUNE					•
HAEMOLYTIC					
ANAEMIAS					1
DIALYSIS				_	
				1	
GASTROINTESTINAL					
DISEASES					11
SYSTEMIC					,
SCLEROSIS					1
ANKYLOSING					,
SPONDYLITIS					1
ACTIVE TRANSPLANT					1
SKIN AND					
HYPODERMIC TISSUE					
DISEASE					1
CUSHING SYNDROME					1
DEMENTIA					
					1
SJOGREN DISEASE					1

HEMATIC AND					
HEMATOPOIETIC					
ORGANS DISEASE					1
ADDISON SYNDROME					1
TUMORS			1		

Rows are comorbidities from database. Columns are categorical variables used in this paper, as derived from original comorbidities

Definition of main comorbidities

Main comorbidities, not reported under the category "Other", had the following definitions in the database, publicly reported at

https://www.dati.lombardia.it/stories/s/Modello-lombardo-per-la-presa-in-carico_20180222/ya5j-7avn

(website in Italian only, accessed 10th may 2020)

ARTERIAL HYPERTENSION

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemptions codes: 031.401, 031.405, D31.401, D31.405, 0031, 0031.405.0, 031.405.0)

Hospitalization in the last 5 years with an ICD9 code 401, 403, 405 diagnosis

Hospitalization in the last 5 years with a DRG code type (134)

Medications prescribed during the last year presenting the following ATC code (C02AC01, C02CA04, C03, C07,C08C, C09 (DDD>50%)

Hypertension was redefined as arterial hypertension plus any patient taking anti-hypertensive medications (see drug categories above)

HYPERCHOLESTEROLEMIA

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemption code: 025*)

Hospitalization in the last 5 years with an ICD9 code 272.0, 272.2, 272.4, 272.9 diagnosis

Medications prescribed during the last year presenting the following ATC code (C10AA (DDD>50%))

DIABETES MELLITUS TYPE 2, UNCOMPLICATED

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemption code: 013.250, only when the latter is given to patients >= 35 years old)

Hospitalization in the last 5 years with an ICD9 code 250.00, 250.02, 250.10, 250.12, 250.20, 250.22, 250.30, 250.32 diagnosis

Hospitalization in the last 5 years with a DGR code type (294)

Medications prescribed during the last year presenting the following ATC code (A10B* (DDD>50%))

DIABETES MELLITUS TYPE 2, COMPLICATED

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Hospitalization in the last 5 years with an ICD9 code 250.42, 250.40, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90, 250.92, 362.01-363.07,357.2 diagnosis

Hospitalization in the last 5 years with a DRG code type (285)

©2020 American Medical Association. All rights reserved.

Medications prescribed during the last year presenting the following ATC code (N03AX16, N03AX12 (DDD>30%)) Outpatient visit performing ambulatory performances type 1433, 1434, 1475, 96591, 96592, 96593, 96594, 96595, 96596)

CARDIOVASCULAR DISEASES

ARTERIAL VASCULOPATHY

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemptions codes: 02.440, 002.441.2, 002.441.4, 002.441.7, 002.441.9, 002.442, 002.444, 002.447.0, 002.447.1, 002.447.6)

Hospitalization in the last 5 years with an ICD9 code 440, 441,442, 443.1, 443.2, 444, 445, 447 diagnosis Hospitalization in the last 5 years with a surgical intervention having code: 3924, 3925, 3926, 3950, 3951, 3952, 3954, 3956, 3957, 3958, 3971, 3972, 3973, 3974, 3979, 3990)

HEART FAILURE

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemption code: 021.428)

Hospitalization in the last 5 years with an ICD9 code 428 diagnosis

Medications prescribed during the last year presenting the following ATC code (C09A, C09C, (DDD>50%) C03CA, C03CB, C03EB (DDD>50%))

VALVULAR CARDIOMYOPATHY

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemptions codes: 002.394, 002.395, 002.396, 002.397, 002.424, 002.745, 002.746, 002.747;002.V42.2, 002.V43.3)

Hospitalization in the last 5 years with an ICD9 code 394, 397, 745, 747, V42.2, V43.3 diagnosis

Hospitalization in the last 5 years with a surgical intervention having code: 35

ISCHEMIC CARDIOMYOPATHY

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemptions codes: 002.414)

Hospitalization in the last 5 years with an ICD9 code 410, 414 diagnosis

Hospitalization in the last 5 years with a surgical intervention having code: 36

Medications prescribed during the last year presenting the following ATC code (C01DA*(DDD>50%))

ARRHYTHMIC CARDIOMYOPATHY

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemptions codes: 002.426, 002.427, 002.V45.0)

Hospitalization in the last 5 years with an ICD9 code 426, 427, V45.0 diagnosis

Hospitalization in the last 5 years with a surgical intervention having code: 3765, 3766, 3768, 3770, 3787, 3789, 3796

Medications prescribed during the last year presenting the following ATC code (C01B* (DDD>50%))

Outpatient visit performing ambulatory performance type 89481

©2020 American Medical Association. All rights reserved.

NON-ARRHYTHMIC CARDIOMYOPATHY

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemptions codes: 031.402, 031.403, 002.416, 002.417, 002.429.4, 0031.402, 0031.403)

Hospitalization in the last 5 years with an ICD9 code 402, 404, 415, 416, 417, 425, 4294 diagnosis

Medications prescribed during the last year presenting the following ATC code (C02KX01, C02KX02, C02KX03, G04BE03, G04BE08, B01AC09 (DDD>50%))

MALIGNANCY

ACTIVE NEOPLASIA

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemption code: 048)

Hospitalization in the last 5 years with an ICD9 code 140, 208, V580, V581 diagnosis

Hospitalization in the last 5 years with a surgical intervention having code: 9925

Medications prescribed during the last year presenting the following ATC code (L01* (excluding L01AB01 and L01AA01))

Outpatient visit performing ambulatory performances type 9925, 9224, 92251, 92271, 92273, 92275, 92283, 92284, 92285, 92286, 38991, 38992, 8901M, 897C1, 9229H, 9229J, 9229K, 9229L, 9229M, MAC01, MAC02, MAC03, MAC04)

NEOPLASIA, FOLLOW UP

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemption code: 048)

Hospitalization in the last 5 years with an ICD9 code 140, 208, V580, V581 diagnosis

Hospitalization in the last 5 years with a surgical intervention having code: 9925

Medications prescribed during the last year presenting the following ATC code (L01* (excluding L01AB01 and L01AA01))

Outpatient visit performing ambulatory performances type 9925, 9224, 92251, 92271, 92273, 92275, 92283, 92284, 92285, 92286, 38991, 38992, 8901M, 897C1, 9229H, 9229J, 9229K, 9229L, 9229M, MAC01, MAC02, MAC03, MAC04)

NEOPLASIA, REMISSION

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions being at list 5 year active and given in the last 10 years (exemption code: 048) Hospitalization in the last 10 years, but over the 5th year since diagnosis, with an ICD9 code 140, 208, V580, V581 diagnosis

Hospitalization in the last 10 years, but over the 5th year since diagnosis, with a surgical intervention having code: 9925 Medications prescribed during the last 10 years, but over the 5th year since diagnosis, presenting the following ATC code (L01* (excluding L01AB01 and L01AA01))

Outpatient visit performing ambulatory performances type 9925, 9224, 92251, 92271, 92273, 92275, 92283, 92284, 92285, 92286, 38991, 38992, 8901M, 897C1, 9229H, 9229J, 9229K, 9229L, 9229M, MAC01, MAC02, MAC03, MAC04)

COPD

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemption code: 057)

Hospitalization in the last 5 years with an ICD9 code 491, 492, 494, 496 diagnosis

Medications prescribed during the last year presenting the following ATC code (R03* (DDD>30%) for patients over >=45 years old)

CHRONIC KIDNEY DISEASE

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemptions codes: 023, 031.403, 031.404, 0031.403, 0031.404, 061, 062)

Hospitalization in the last 5 years with an ICD9 code V56, 585, 586 diagnosis

Hospitalization in the last 5 years with a DRG code: 316, 317

Medications prescribed during the last year presenting the following ATC code (V03AE02, V03AE03, V03AE01, H05BX01, H05BX02 (DDD>50%))

DIALYSIS

Tracers

Outpatient visit performing at least 70 ambulatory performances type 3995, 5498

LIVER DISEASES

LIVER CIRRHOSIS

Tracers

We associate this pathology to an assisted patient if, at least, one of the following conditions is fulfilled:

Medical exemptions given in the last 10 years (exemption code: 008)

Hospitalization in the last 5 years with an ICD9 code 571.2, 571.5, 571.6, 571.8, 572.3, 456.0, 456.1, 456.2 diagnosis

CHRONIC HEPATITIS

Tracers

We associate this pathology to a patient if, at least, one of the following conditions is fulfilled:


Medical exemptions given in the last 10 years (exemption code: 016)

Hospitalization in the last 5 years with an ICD9 code 070 diagnosis

Medications prescribed during the last year presenting the following ATC code (L03AB04, L03AB05, L03AB06, L03AB09, L03AB10, L03AB11, L03AB12, L03AB60, L03AB61 (DDD>50%), J05AE14, J05AX16, J05AX68, J05AX67, J05AX14, J05AX65, J05AX15)


eFigure 1. Missing Data

Percentage of missing data for physiological variables, comorbidities, and medications are reported




DM=Diabetes Mellitus, COPD= chronic obstructive pulmonary disease, CKD= chronic kidney disease, ARB=angiotensin receptor blocker, ACE-I=Angiotensin I Converting Enzyme. ICU discharge date includes missing data due to patients still in ICU


eFigure 2. Outcomes According to ICU Admission Date



eFigure 3. Multivariable Model Including Baseline Characteristics, Comorbidities, Medications, and Physiological Variables at Admission



eFigure 4. Survival According to Use of Noninvasive Ventilation at Admission



eTable 1. Different Characteristics of Patients According to Noninvasive Ventilation or Invasive Mechanical Ventilation at Admission

	n	NIV (n=350) IMV (n=2929)		Р
				NIV vs IMV
		Median	Median	
		(IQR)	(IQR)	
AGE	3279	62 (53-70)	63 (56-69)	0.37
PaO2	2895	88 (71-110)	95 (77-130)	<0.001
FiO2	2953	60 (50-80)	70 (60-90)	<0.001
PaO2/FiO2	2882	144 (104-200)	145 (102-201)	0.12
PEEP	3020	10 (10-14)	13 (11-15)	<0.001
Hazard ratio for mortality*	127 events for NIV, 1514 events for IMV	0.62 (0.52-0.75)	1.6 (1.34-1.92)	<0.001

^{* =}Non-invasive mechanical ventilation, IMV=Invasive mechanical ventilation

eTable 2. Previous Medication Use in the Overall Population and in the Subpopulation of Patients With History of Hypertension

		Overall population		
	Number of events	Event ratio*	Hazard ratio	Р
Ace-I	435	17.6 (15.9-19.3)	1.58 (1.42-1.75)	<0.001
ARB	404	15.9 (14.4-17.6)	1.43 (1.28-1.6)	<0.001
B-Blockers	427	17.5 (15.9-19.2)	1.6 (1.44-1.78)	<0.001
Statins	479	19.4 (17.7-21.2)	1.76 (1.59-1.95)	<0.001
Immunosuppressors ^a	170	13.4 (11.5-15.6)	1.18 (1.01-1.38)	0.038
Diuretics	137	19.8 (16.6-23.4)	1.68 (1.41-2.0)	<0.001
Anti-platelets drugs	276	21.2 (18.7-23.8)	1.81 (1.59-2.06)	<0.001
Anticoagulants	144	14.8 (12.5-17.4)	1.29 (1.09-1.53)	0.003
	Рорг	ulation of hypertensive	patients	
	Dead	Alive	Total	Р
	N=924 (57.5%)	N=684 (42.5%)	N= 1608	
ACE-I	435	17.6 (15.9-19.3)	1.15 (1.01-1.3)	0.033
ARB	404	15.9 (14.4-17.6)	1.01 (0.89-1.15)	0.9
B-Blockers	427	17.5 (15.9-19.3)	1.18 (1.04-1.34)	0.013
Statins	406	20.6 (18.7-22.7)	1.42 (1.25-1.61)	<0.001
Diuretics	132	20.7 (17.3-24.6)	1.31 (1.09-1.58)	0.004

^{*}Event ratio per 1000 patient days. ARB=angiotensin receptor blocker, ACE-I=Angiotensin I Converting Enzyme *95% of which were corticosteroids